When it comes to rare cancers, information can be hard to find — and for patients and families, that lack of clarity can be one of the hardest parts. I’m passionate about sharing stories that help make complex medical terms and treatment decisions easier to understand.

Today’s post sheds light on an exceptionally rare case — one that shows both the challenges and hope that come with innovation in appendix and ovarian tumor care.

What Is LAMN?

A low-grade appendiceal mucinous neoplasm (LAMN) is a rare type of tumor that begins in the appendix. These tumors produce a thick, jelly-like substance called mucin.

Sometimes that mucin leaks into the abdomen, where it can build up and cause a condition known as pseudomyxoma peritonei (PMP). This can make the stomach swell and feel full — not because of food or fat, but because of the mucin itself. PMP can affect how organs like the intestines and liver function, which is why careful surgical treatment is so important.

When Two Rare Conditions Collide

In this case, a 44-year-old woman was diagnosed with both LAMN and a mucinous borderline ovarian tumor (MBOT) — a slow-growing tumor in the ovary that also produces mucin. Having both at the same time is extremely rare.

Because there are no standard treatment guidelines for this situation, her care team needed to create a personalized plan, drawing on expertise from surgeons, oncologists, and specialists experienced in peritoneal surface malignancies.

A Personalized Treatment Plan

The doctors used a multimodal approach, meaning they combined several powerful treatments designed to work together:

1. Cytoreductive Surgery (CRS) – a major operation to remove all visible tumor and mucin. The procedure included removing the appendix, part of the colon, both ovaries and fallopian tubes, and the omentum (a fatty layer that lines the abdomen).
2. Modified FOLFIRINOX Chemotherapy – a mix of cancer-fighting drugs that included irinotecan, known for its effectiveness against gastrointestinal cancers.
3. Second-Look Surgery with HIPEC – a planned follow-up surgery using heated chemotherapy (HIPEC) placed directly into the abdomen to kill any remaining cancer cells.

The patient tolerated all of these treatments well.

Results and Hope

One year after treatment, she was disease-free — a remarkable outcome.
This case highlights how individualized treatment and the use of irinotecan-based chemotherapy may improve results for patients with low-grade mucinous tumors, especially when traditional guidelines don’t exist.

Why This Matters

For anyone facing an appendix or mucinous cancer diagnosis, this story is a message of hope. It reminds us that progress often comes from creativity, collaboration, and courage — both from the medical team and from patients willing to try new approaches.

There may not always be a “standard treatment,” but there are dedicated doctors and researchers working every day to expand what’s possible.

Spreading Awareness

If you or someone you love has been diagnosed with appendix cancer or pseudomyxoma peritonei (PMP), you are not alone.
Learning more and connecting with others can make a world of difference.

Annals of Medicine: Uncommon Multimodal Management Approach